WHANIN PHARM CO.,LTD

016580KOSPIPharmaceuticals

WHANIN PHARM CO.,LTD (016580, KOSPI) reported KRW 255bn revenue in 2025.

Reported financials

Figures are as filed with the Korean regulator, in billions of won (KRW bn). We do not convert to dollars — an exchange rate would be a number we made up, not one the company reported.

YearRevenueOperating profitNet profitAssetsEquityBasis
20211783126353317Consolidated
20221993024369334Consolidated
20232303030401358Consolidated
20242602123425376Consolidated
20252551314479421Consolidated

Ratios, year by year

Each ratio is computed inside its own year. A dash means the input was missing or the denominator was zero — not that the value is zero.

YearOperating marginNet marginEquity / assetsReturn on equity
202117.6%14.9%89.8%8.3%
202215%11.9%90.4%7.1%
202313.1%12.9%89.3%8.3%
20248.3%9%88.5%6.2%
20255.1%5.3%87.9%3.2%

Revenue moved 43.6% between 2021 and 2025.

Net profit was positive in the 5 most recent consecutive years on file — every year we hold. Counted from the 5 years in which the company filed a net-profit line — a year with no filing is skipped, not read as a loss.

These are arithmetic, not judgements. We do not say whether a margin is good or bad, and we do not rank companies against each other.

Market size

Market capitalisationKRW 193bn
Close priceKRW 10,370
Listed shares18,600,070
Price as of20260909

Market capitalisation is what buyers are betting the company is worth. It is not something the company produced, so we never present it as output or productivity.

When it was founded

The incorporation date on the company's registration record, as filed with Korea's Financial Supervisory Service. This is when the company was legally formed — not when it first listed, and not when the business it grew out of began trading.

Incorporated

Who runs it

Registered representative directors — in Korea this is the office a CEO holds. Filed with the Financial Supervisory Service (DART). A Korean company can register more than one, and the title beside each name is the rank they carry inside the company.

NameTitleBoard seatYears in post
Lee Gwang-sik (이광식)Representative Director (CEO), ChairmanInside director47 years
Lee Won-beom (이원범)Representative Director (CEO), PresidentInside director20 years

Roman spellings are ours, converted from the Korean filing. The person may spell their own name differently in English. The Korean name in brackets is what was filed.

Workforce — a side measure, not the main one

Employees (2025)671
Women247 (36.8%)
Average tenure6.3 years
Annual pay, menKRW 86,000,000
Annual pay, womenKRW 57,000,000
Pay ratio, women to men66.3%

Other companies in Pharmaceuticals

181 listed companies file under this classification. Showing 12.

See the whole Pharmaceuticals list →